ESPR
Esperion Therapeutics Inc
3.20$
+0.0%
vs. previous close
Closing price · As of: Jul 15, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 1999 | 2000 | 2001 | 2002 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -897,700.0% | – | – | – | – | -0.4% | – | – | – | – | -80.6% | -47.4% | -37.4% | -336.3% | -231.6% | -116.5% | -7.1% | -3.2% | |
| – | -102,500.0% | – | – | – | – | 0.0% | – | – | – | – | 0.1% | 0.2% | 0.2% | 0.8% | 0.7% | 0.1% | 0.0% | 0.0% | |
| – | – | – | – | – | – | 0.0% | – | – | – | – | 13.0% | 17.4% | 12.5% | 31.0% | 20.2% | 10.3% | 3.6% | 2.4% | |
| – | – | – | – | – | – | 0.1% | – | – | – | – | 13.0% | 17.4% | 12.5% | 27.6% | 20.2% | – | – | – | |
| – | 148,750.0% | – | – | – | – | 0.1% | – | – | – | – | 15.8% | -4.9% | -1.9% | -66.9% | -4.5% | 11.8% | -18.2% | -3.6% | |
| – | 67,050.0% | – | – | – | – | 0.0% | – | – | – | – | 0.1% | 0.6% | 5.9% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | |
| – | -101,200.0% | – | – | – | – | -0.4% | – | – | – | – | 76.1% | 43.3% | 9.4% | -64.4% | 10.7% | 36.5% | -0.1% | 0.0% | |
| – | – | – | – | – | – | 0.0% | – | – | – | – | – | – | 133.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| – | – | – | – | – | – | 1.5% | – | – | – | – | 6.4% | 7.9% | -24.2% | 283.6% | 120.4% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | -0.6% | 188.7% | 99.1% | -0.6% | 0.0% | 0.0% | 10.5% | -13.6% | |
| – | 4,205,900.0% | – | – | – | – | 1.8% | – | – | – | – | 5.8% | 91.8% | 88.7% | 341.9% | 43.2% | 43.4% | 26.0% | 9.0% | |
| – | 3,216,200.0% | – | – | – | – | 1.0% | – | – | – | – | 1.4% | 87.7% | 60.6% | -58.7% | -177.7% | -36.6% | 18.8% | 5.7% | |
| – | -964,750.0% | – | – | – | – | -0.4% | – | – | – | – | -80.7% | -48.1% | -43.3% | -336.3% | -231.6% | -116.5% | -7.2% | -3.2% |
Data as of: July 15, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.